These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31400346)

  • 1. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
    Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.
    Agarwal S; Hickey JM; McAdams D; White JA; Sitrin R; Khandke L; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):476-487. PubMed ID: 31589875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.
    McAdams D; Lakatos K; Estrada M; Chen D; Plikaytis B; Sitrin R; White JA
    J Immunol Methods; 2021 Jul; 494():113056. PubMed ID: 33857473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine.
    Lakatos K; McAdams D; White JA; Chen D
    Hum Vaccin Immunother; 2020 Aug; 16(8):1957-1968. PubMed ID: 31995444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine.
    Kumru OS; Saleh-Birdjandi S; Antunez LR; Sayeed E; Robinson D; van den Worm S; Diemer GS; Perez W; Caposio P; Früh K; Joshi SB; Volkin DB
    Vaccine; 2019 Oct; 37(44):6696-6706. PubMed ID: 31548012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens.
    Sawant N; Kaur K; Holland DA; Hickey JM; Agarwal S; Brady JR; Dalvie NC; Tracey MK; Velez-Suberbie ML; Morris SA; Jacob SI; Bracewell DG; Mukhopadhyay TK; Love KR; Love JC; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Mar; 110(3):1042-1053. PubMed ID: 33285182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallization of a nonreplicating rotavirus vaccine candidate.
    Hong MS; Kaur K; Sawant N; Joshi SB; Volkin DB; Braatz RD
    Biotechnol Bioeng; 2021 Apr; 118(4):1750-1756. PubMed ID: 33527346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Propylene Glycol-Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging.
    Mensch CD; Davis HB; Blue JT
    PDA J Pharm Sci Technol; 2015; 69(4):477-98. PubMed ID: 26242785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus.
    Dalvie NC; Brady JR; Crowell LE; Tracey MK; Biedermann AM; Kaur K; Hickey JM; Kristensen DL; Bonnyman AD; Rodriguez-Aponte SA; Whittaker CA; Bok M; Vega C; Mukhopadhyay TK; Joshi SB; Volkin DB; Parreño V; Love KR; Love JC
    Microb Cell Fact; 2021 May; 20(1):94. PubMed ID: 33933073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
    Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
    Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
    Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.
    Toprani VM; Sahni N; Hickey JM; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
    Vaccine; 2017 Oct; 35(41):5471-5480. PubMed ID: 28551040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
    Kumar P; Holland DA; Secrist K; Taskar P; Dotson B; Saleh-Birdjandi S; Adewunmi Y; Doering J; Mantis NJ; Volkin DB; Joshi SB
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.
    Velasquez DE; Jiang B
    Hum Vaccin Immunother; 2019; 15(12):3003-3008. PubMed ID: 31124743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen.
    Clapp T; Munks MW; Trivedi R; Kompella UB; Braun LJ
    Vaccine; 2014 Jun; 32(30):3765-71. PubMed ID: 24856785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
    Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
    J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.